Brief: Epigenomics Q1 Net Loss Narrowed To EUR 3.0 Mln
08/05/2019 07:07
May 8 (Reuters) - Epigenomics AG ECXn.DE :
* DGAP-NEWS: EPIGENOMICS AG REPORTS 2019 FIRST QUARTER FINANCIAL RESULTS
* Q1 TOTAL REVENUE INCREASED TO EUR 331 THOUSAND (Q1 2018: EUR 309 THOUSAND)
* Q1 EBITDA (BEFORE SHARE-BASED PAYMENT EXPENSES) IMPROVED FROM EUR -3.2 MILLION (Q1 2018)
TO EUR
-3.0 MILLION
* Q1 NET LOSS FOR PERIOD IMPROVED TO EUR -3.0 MILLION (Q1 2018: EUR -3.2 MILLION)
* OUTLOOK 2019: CONFIRMS REVENUE EXPECTATION IN 2019 WITHIN RANGE OF EUR 3.0 MILLION TO EUR
6.0
MILLION
* OUTLOOK 2019: SEES EBITDA BEFORE SHARE-BASED PAYMENT EXPENSES TO REMAIN UNCHANGED FROM
PREVIOUS
YEAR'S GUIDANCE
Source text for Eikon: ID:nEQ30wxb5a
Further company coverage: ECXn.DE
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Epigenomics AG
See all newsU.S. FDA advisers back approval for Guardant's blood-based cancer test (updated)
U.S. FDA advisers back approval for Guardant's cancer test
Brief: Epigenomics Says Closing Of Agreement On The Acquisition Of Almost All Assets And Adjustment Of Guidance For 2023
Brief: Epigenomics AG Says It Entered Into Agreement On The Acquisition Of Almost All Assets With New Day Diagnostics LLC
Brief: Epigenomics Says Chief Scientific Officer Andrew Lukowiak Resigns